Ocugen CEO to present at the NobleCon20 conference
The presentation and the moderated Q&A is scheduled for Tuesday, December 3, 2024 in Presentation Room 3 at 1:30 pm ET.
(Image credit: AdobeStock/stockpro)
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference. This conference is set to take place at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL from December 3 to 4, 2024.
In the press release from the company regarding this announcement, Musunuri said, “Every year, NobleCon showcases emerging growth companies from a variety of industries to a relevant investor audience. I look forward to sharing an update on our clinical programs for attendees who may not yet be familiar with the Ocugen story.”
The presentation and the moderated Q&A is scheduled for Tuesday, December 3, 2024 in Presentation Room 3 at 1:30 pm ET.
More information
The company also noted that additional members of Ocugen’s executive team will conduct one-on-one meetings with investors to highlight the company’s business and clinical development strategy across its unique modifier gene therapy platform.
Virtual presentation viewing
A high-definition video webcast of the presentation will be available the following day in the complete catalog of presentations available at events section of Ocugen’s website, and as part of a Noble Capital Markets’ Conference website, and on Channelchek the investor portal created by Noble. The webcast will be archived on the Company's website, the NobleCon website, and Channelchek.com for 90 days following the event.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation —forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on About Noble Capital Markets, Inc. X and LinkedIn.
